Tagged with B

Egypt Ahmed Zaghloul, CEO of October Pharma, stresses the need for better infrastructure for biosimilars in Egypt to stay competitive on a global level. He also highlights October Pharma’s ambitious export strategy, targeting markets in the Gulf Region and South East Asia.   Production costs are rising, and pricing pressures continue,…

Opinion Tom Achoki of Mass Sciences explores the possibilities that better access to high-quality real-world data will create for accelerating novel drug discovery and ultimately improving patient outcomes.   Proactive decision makers within the biopharmaceutical industry need to find innovative ways to bridge the existing RWD gaps within their organization The…

China Dr Jun Bao, appointed president and CEO of Impact Therapeutics in October 2018, shares his aspirations for Impact to be a leader in synthetic lethality in oncology; the importance of ‘operating locally but selling globally’; his learnings from his distinguished career across biotech and pharma companies in the US and…

France Elie Lobel, CEO of Orange Healthcare, explains how digitalization is bringing together stakeholders from across the healthcare continuum, allowing increased information exchange and connectivity. Lobel also gives insight into the latest projects the company is working on to digitally transform healthcare.   Access to healthcare is a critical issue around…

France Vincent Pont, president of Laboratoire Arrow, explains the company’s history, its collaboration with Aurobindo, the Indian generic pharmaceuticals group, the company’s unique positioning as a leader in the generic hospital sector, and its future growth strategies.   Generics companies need a wide portfolio to meet all of the generics needs…

France Bertrand de Lavenne, general manager of Mylan France, explains how the affiliate is positioned within the group’s operations and how the Mylan strategy is to be a key actor in connecting the health network around patient needs. De Lavenne also shares his view on the French pharmaceutical market and the…

Spain Luciano Conde, CEO, and Jose Luis Fumanal, VP of Sales and Marketing at Noventure, discuss how they set up the company in 2015 and their secret to achieving success in such a short period of time. Furthermore, they highlight what they look for in potential partners and their aspirations for…

Germany Peter Homberg of Dentons Germany examines the regulatory status quo around the free sale of products containing cannabidiol (CBD) across Europe. Although deregulation efforts are underway, Homberg argues that the trade in these products is not as free and unregulated as it may initially seem.   CBD products that are…

China Lorena Di Carlo, a Lundbeck veteran, shares her first impressions of her six months as general manager of Lundbeck China, the strategic significance of China to Lundbeck’s global organization, the company’s commitment to patient-centricity, disease awareness and medical education in the area of brain diseases, and her strategic priorities for…

Spain Ian Wilders, managing director of Labo’Life, a Spanish micro-immunotherapy specialist, discusses the company’s history and the importance of regulatory reform in giving them greater market access and shifting the mindset of doctors. Furthermore, he touches on the company’s international strategy and the importance of a personalized care approach.   Our…

France Pascal Girin, CEO of BALT, shares how his rich career in neurovascular medical technology helped him to transform the company from a small R&D pure player into an international market leader. Girin goes on to explain the high key growth strategy he is implementing and the impact that BALT’s products…

China Dr John Yu, co-founder and CEO of CGeneTech, shares the exciting story behind the company’s establishment in 2010; its balanced philosophy on new drug development and the progress of their flagship Cetagliptin, a Dipeptidyl peptidase-4 (DPP-4) inhibitor of diabetes drug in Phase I clinical trials at the moment; the importance…